Welcome to our dedicated page for OnKure Therapeutics news (Ticker: OKUR), a resource for investors and traders seeking the latest updates and insights on OnKure Therapeutics stock.
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of precision medicines targeting oncogenic and pathologically activated PI3Kα. The company regularly issues updates on its lead program, OKI-219, a selective PI3KαH1047R inhibitor being evaluated in the PIKture-01 phase 1 trial in advanced solid tumors, including multiple subtypes of metastatic breast cancer.
News about OnKure often covers clinical progress in PIKture-01, such as enrollment status, dose escalation milestones, and preliminary safety, tolerability, and pharmacokinetic data. The company has reported encouraging early results for OKI-219, including descriptions of tolerability and exposure levels, and has detailed the evolution of the trial from monotherapy cohorts to combination and triplet arms with fulvestrant, ribociclib, trastuzumab, and tucatinib in HR+ and HER2+ metastatic breast cancer settings.
Investors and observers can also expect press releases on OnKure’s broader PI3Kα portfolio, including its next-generation pan-mutant selective program and discovery-stage efforts targeting additional PI3Kα mutations such as E542K and E545K. The company has highlighted preclinical data, including combination studies of OKI-219 with standard-of-care therapies in PI3KαH1047R mutant breast cancer models, and has announced scientific presentations at meetings like the San Antonio Breast Cancer Symposium.
In addition, OnKure reports quarterly and annual financial results, business updates, and participation in healthcare and biotechnology investor conferences. These communications provide insight into its cash position, operating expenses, planned milestones, and capital markets activities, including an at-the-market equity offering program disclosed in an 8-K filing. Bookmark this page to follow the latest OKUR news, including clinical updates, pipeline developments, financial disclosures, and corporate presentations.
OnKure Therapeutics (NASDAQ: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., President and CEO, will deliver a corporate presentation on November 18, 2024, at 1:50 p.m. ET in New York.
The presentation will be accessible via live webcast through the 'Events' section of OnKure's website, with a replay available for approximately 90 days following the event.
OnKure Therapeutics (NASDAQ: OKUR) announced the presentation of two abstracts featuring preliminary clinical and preclinical data for OKI-219, their mutant-selective PI3KαH1047R inhibitor, at the 2024 San Antonio Breast Cancer Symposium (SABCS). The presentations will cover results from the PIKture-01 first-in-human study and preclinical data on OKI-219's enhanced activity in breast cancer models. The symposium will be held both virtually and in-person from December 10-13, 2024. OnKure will host a conference call on December 13 to discuss the preliminary data and provide a corporate update.